# US 2026/0098018 A1 · Bicyclic 1,4-diazepanones and therapeutic uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098018 A1
- Document ID: US20260098018A1
- Status: Published application
- Kind: A1
- Application number: 19/261,878
- Filed: 2025-07-07
- Published: 2026-04-09
- Earliest claimed: 2020-11-06
- Assignees: Cytokinetics, Inc.
- Applicants: Cytokinetics, Inc.
- Inventors: Bradley P. MORGAN; Chris EVANS; Pu-Ping LU; Makoto YAMASAKI; Wenyue WANG; Scott COLLIBEE; Takuya MAKINO; Kazuyuki TSUCHIYA; Toshio KUROSAKI; Susumu YAMAKI; Eriko HONJO; Yuka KOIZUMI; Naoto KATOH; Ryuichi SEKIOKA; Ikumi KURIWAKI
- Web page: https://patentgrep.com/patent/US20260098018A1

## CPC

- C07D 243/14: 1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C07D 243/24: Oxygen atoms
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 403/14: containing three or more hetero rings
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/08: linked by a carbon chain containing alicyclic rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 471/10: Spiro-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 498/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.

## Claims

### Claim at position 1

1-63. (canceled)

### Claim 64

A method of preparing Compound 10
or a salt thereof, comprising converting (S)-3-((S)-sec-butyl)-6-fluoro-1,3,4,5-tetrahydro-2H-pyrido[3,4-e][1,4]diazepin-2-one,
or a salt thereof, to Compound 10, or a salt thereof.

### Claim 65 (depends on 64)

The method of claim 64, wherein the converting (S)-3-((S)-sec-butyl)-6-fluoro-1,3,4,5-tetrahydro-2H-pyrido[3,4-e][1,4]diazepin-2-one, or a salt thereof, to Compound 10, or a salt thereof, comprises reacting the (S)-3-((S)-sec-butyl)-6-fluoro-1,3,4,5-tetrahydro-2H-pyrido[3,4-e][1,4]diazepin-2-one, or salt thereof, with potassium cyanate.

### Claim 66 (depends on 64)

The method of claim 64, wherein the converting (S)-3-((S)-sec-butyl)-6-fluoro-1,3,4,5-tetrahydro-2H-pyrido[3,4-e][1,4]diazepin-2-one, or a salt thereof, to Compound 10, or a salt thereof, is performed in the presence of an acid.

### Claim 67 (depends on 66)

The method of claim 66, wherein the acid is acetic acid.

### Claim 68 (depends on 64)

The method of claim 64, wherein the converting (S)-3-((S)-sec-butyl)-6-fluoro-1,3,4,5-tetrahydro-2H-pyrido[3,4-e][1,4]diazepin-2-one, or a salt thereof, to Compound 10, or a salt, is performed in methyl tert-butyl ether.

### Claim 69 (depends on 64)

The method of claim 64, comprising obtaining the (S)-3-((S)-sec-butyl)-6-fluoro-1,3,4,5-tetrahydro-2H-pyrido[3,4-e][1,4]diazepin-2-one, or salt thereof, by converting methyl((3-amino-5-fluoropyridin-4-yl)methyl)-L-isoleucinate,
or a salt thereof.

### Claim 70 (depends on 69)

The method of claim 69, wherein the converting methyl((3-amino-5-fluoropyridin-4-yl)methyl)-L-isoleucinate, or salt thereof, is performed in the presence of a Lewis acid.

### Claim 71 (depends on 69)

The method of claim 69, wherein the converting methyl((3-amino-5-fluoropyridin-4-yl)methyl)-L-isoleucinate, or salt thereof, is performed in the presence of trimethylaluminum.

### Claim 72 (depends on 69)

The method of claim 69, wherein the converting methyl((3-amino-5-fluoropyridin-4-yl)methyl)-L-isoleucinate, or salt thereof, is performed in the presence of sodium bis(trimethylsilyl)amide.

### Claim 73 (depends on 69)

The method of claim 69, wherein the converting methyl((3-amino-5-fluoropyridin-4-yl)methyl)-L-isoleucinate, or salt thereof, is performed in toluene.

### Claim 74 (depends on 69)

The method of claim 69, wherein the converting methyl((3-amino-5-fluoropyridin-4-yl)methyl)-L-isoleucinate, or salt thereof, is performed in tetrahydrofuran.

### Claim 75 (depends on 69)

The method of claim 69, comprising obtaining the methyl((3-amino-5-fluoropyridin-4-yl)methyl)-L-isoleucinate, or salt thereof, by reacting 3-amino-5-fluoroisonicotinaldehyde,
or a salt thereof, with methyl L-isoleucinate, or a salt thereof.

### Claim 76 (depends on 75)

The method of claim 75, wherein the reacting with methyl L-isoleucinate, or a salt thereof is performed in the presence of sodium triacetoxyborohydride.

### Claim 77 (depends on 75)

The method of claim 75, comprising obtaining the 3-amino-5-fluoroisonicotinaldehyde, or salt thereof, by reacting tert-butyl N-(5-fluoro-4-formylpyridin-3-yl)carbamate,
or a salt thereof, with a deprotecting agent.

### Claim 78 (depends on 77)

The method of claim 77, wherein the deprotecting agent is hydrochloric acid.

### Claim 79 (depends on 77)

The method of claim 77, comprising obtaining the tert-butyl N-(5-fluoro-4-formylpyridin-3-yl)carbamate, or salt thereof, by reacting tert-butyl (5-fluoropyridin-3-yl)carbamate
or a salt thereof, with an organolithium reagent and dimethylformamide.

### Claim 80 (depends on 79)

The method of claim 79, wherein the organolithium reagent is lithium diisopropylamide.

### Claim 81 (depends on 79)

The method of claim 79, wherein the organolithium reagent is n-butyllithium.

### Claim 82 (depends on 81)

The method of claim 81, wherein the reacting with n-butyllithium is performed in the presence of N,N,N′,N′-tetramethylethylenediamine.

### Claim 83 (depends on 79)

The method of claim 79, comprising obtaining the tert-butyl (5-fluoropyridin-3-yl)carbamate, or salt thereof, by reacting 5-fluoropyridin-3-amine
or a salt thereof, with di-tert-butyl decarbonate.

### Claim 84 (depends on 83)

The method of claim 83, wherein the reacting with di-tert-butyl decarbonate is performed in the presence of 4-dimethylaminopyridine.

### Claim 85

A compound, wherein the compound is methyl((3-amino-5-fluoropyridin-4-yl)methyl)-L-isoleucinate
or a salt thereof.

### Claim 86

A compound, wherein the compound is (S)-3-((S)-sec-butyl)-6-fluoro-1,3,4,5-tetrahydro-2H-pyrido[3,4-e][1,4]diazepin-2-one,
or a salt thereof.
